198 related articles for article (PubMed ID: 21051091)
21. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model.
Chuang TF; Lee SC; Liao KW; Hsiao YW; Lo CH; Chiang BL; Lin XZ; Tao MH; Chu RM
Int J Cancer; 2009 Aug; 125(3):698-707. PubMed ID: 19431145
[TBL] [Abstract][Full Text] [Related]
22. Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy.
Gonzalez CM; Griffey SM; Naydan DK; Flores E; Cepeda R; Cattaneo G; Madewell BR
J Comp Pathol; 2000 May; 122(4):241-8. PubMed ID: 10805977
[TBL] [Abstract][Full Text] [Related]
23. Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens.
Turkeri L; Onol FF; Ozyurek M
Urol Oncol; 2010; 28(3):290-5. PubMed ID: 19362861
[TBL] [Abstract][Full Text] [Related]
24. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
25. [Inducing specific antitumor effects on osteosarcoma by fused vaccine of rat dendritic cells].
Yu Z; Fan QY; Ma BA; Hao XB; Long H
Ai Zheng; 2005 Mar; 24(3):285-91. PubMed ID: 15757528
[TBL] [Abstract][Full Text] [Related]
26. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
Foley R; Tozer R; Wan Y
Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
[TBL] [Abstract][Full Text] [Related]
27. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
28. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
29. The changing global distribution and prevalence of canine transmissible venereal tumour.
Strakova A; Murchison EP
BMC Vet Res; 2014 Sep; 10():168. PubMed ID: 25186078
[TBL] [Abstract][Full Text] [Related]
30. Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review).
Yang TJ
Anticancer Res; 1988; 8(1):93-5. PubMed ID: 3282476
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice.
Hu Z; Liu S; Mai X; Hu Z; Liu C
Cell Immunol; 2010; 262(2):112-9. PubMed ID: 20167310
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
34. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
35. Clonally transmissible cancers in dogs and Tasmanian devils.
Murchison EP
Oncogene; 2008 Dec; 27 Suppl 2():S19-30. PubMed ID: 19956175
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a genetic assay for canine transmissible venereal tumour diagnosis in Brazil.
Castro KF; Strakova A; Tinucci-Costa M; Murchison EP
Vet Comp Oncol; 2017 Jun; 15(2):615-618. PubMed ID: 27135875
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological study of canine transmissible venereal tumour in leishmaniotic dogs.
Marino G; Gaglio G; Zanghì A
J Small Anim Pract; 2012 Jun; 53(6):323-7. PubMed ID: 22489831
[TBL] [Abstract][Full Text] [Related]
38. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine.
Orentas RJ; Schauer D; Bin Q; Johnson BD
Cell Immunol; 2001 Oct; 213(1):4-13. PubMed ID: 11747351
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
40. Occurrence of the acquired immunity in early vertebrates due to danger of transmissible cancers similar to canine venereal tumors.
Kurbel S; Plestina S; Vrbanec D
Med Hypotheses; 2007; 68(5):1185-6. PubMed ID: 17110053
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
